Magdalena Zemelka-Wiacek

Prof. Dr. Magdalena Zemelka-Wiacek

Department of Clinical Immunology, Wroclaw Medical University, Wrocław, Dolnośląskie, Poland
orcid
Excited to be Guest Editor for IJMS Special Issue on micro- ...

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Environmental Research
Verified
Journal Article
Open access
EWEwa Winiarska
Ewa Winiarska
Marek JutelMarek Jutel
Marek Jutel
Magdalena Zemelka-WiacekMagdalena Zemelka-Wiacek
Magdalena Zemelka-Wiacek
Plastics are used all over the world. Unfortunately, due to limited biodegradation, plastics cause a significant level of environmental pollution. The smallest recognized to date are termed nanoplastics (1 nm [nm] up to 1 μm [μm]) and microplastics (1 μm-5 mm). These nano- and microplastics can enter the human body through the respiratory system via inhalation, the digestive tract via consumption of contaminated food and water, or penetration through the skin via cosmetics and clothes contact. Bioaccumulation of plastics in the human body can potentially lead to a range of health issues, including respiratory disorders like lung cancer, asthma and hypersensitivity pneumonitis, neurological symptoms such as fatigue and dizziness, inflammatory bowel disease and even disturbances in gut microbiota. Most studies to date have confirmed that nano- and microplastics can induce apoptosis in cells and have genotoxic and cytotoxic effects. Understanding the cellular and molecular mechanisms of plastics' actions may help extrapolate the risks to humans. The article provides a comprehensive review of articles in databases regarding the impact of nano- and microplastics on human health. The review included retrospective studies and case reports of people exposed to nanoplastics and microplastics. This research highlights the need for further research to fully understand the extent of the impact of plastics on human health.

10 October 2023 in Allergy
Verified
Journal Article
Closed access
Marek JutelMarek Jutel
Marek Jutel
IAIoana Agache
Ioana Agache
Magdalena Zemelka-WiacekMagdalena Zemelka-Wiacek
Magdalena Zemelka-Wiacek
MAMubeccel Akdis
Mubeccel Akdis
TCTomás Chivato
Tomás Chivato
CACezmi A. Akdis
Cezmi A. Akdis

14 August 2021 in Allergy
Verified
Journal Article
Open access
PDF file
IAIoana Agache
Ioana Agache
Ibon Eguíluz-GraciaIbon Eguíluz-Gracia
Ibon Eguíluz-Gracia
CCCatalina Cojanu
Catalina Cojanu
ALAlexandru Georgian Laculiceanu
Alexandru Georgian Laculiceanu
SGStefano del Giacco
Stefano del Giacco
MJMarek Jutel
Marek Jutel
Last year brought a significant advance in asthma management, unyielding to the pressure of the pandemics. Novel key findings in asthma pathogenesis focus on the resident cell compartment, epigenetics and the innate immune system. The precision immunology unbiased approach was supplemented with novel tools and greatly facilitated by the use of artificial intelligence. Several randomised clinical trials and good quality real‐world evidence shed new light on asthma treatment and supported the revision of several asthma guidelines (GINA, Expert Panel Report 3, ERS/ATS guidelines on severe asthma) and the conception of new ones (EAACI Guidelines for the use of biologicals in severe asthma). Integrating asthma management within the broader context of Planetary Health has been put forward. In this review, recently published articles and clinical trials are summarised and discussed with the goal to provide clinicians and researchers with a concise update on asthma research from a translational perspective.

Verified
Journal Article
Open access
PDF file
Sylwia Smolinska-WilczynskaSylwia Smolinska-Wilczynska
Sylwia Smolinska-Wilczynska
FPFlorin-Dan Popescu
Florin-Dan Popescu
Magdalena Zemelka-WiacekMagdalena Zemelka-Wiacek
Magdalena Zemelka-Wiacek
Objective: This review aims to comprehensively evaluate the current evidence on the role of prebiotics, probiotics, synbiotics, and postbiotics—collectively referred to as “biotics”—in modulating the human gut microbiota and enhancing intestinal epithelial integrity. Findings: Biotics exert their beneficial effects through several mechanisms, including by promoting the growth of beneficial microbes, producing short-chain fatty acids (SCFAs), strengthening the gut barrier, and regulating immune responses. Prebiotics selectively stimulate beneficial bacteria, probiotics introduce live microorganisms with therapeutic functions, synbiotics combine the strengths of both, and postbiotics offer non-viable microbial components and metabolites that mimic probiotic benefits with enhanced safety profiles. Each type of biotic demonstrates unique and complementary effects across a range of conditions, such as inflammatory bowel disease, irritable bowel syndrome, obesity, constipation, and antibiotic-associated diarrhea. Implications: As disruptions in the gut microbiota and intestinal barrier are increasingly linked to chronic and immune-mediated diseases, leveraging biotics offers promising avenues for personalized nutrition, preventive healthcare, and adjunct therapies. The integration of biotics into clinical and dietary strategies may significantly contribute to improving gastrointestinal and systemic health.

20 November 2023 in Allergy
Verified
Journal Article
Open access
Magdalena Zemelka-WiacekMagdalena Zemelka-Wiacek
Magdalena Zemelka-Wiacek
IAIoana Agache
Ioana Agache
CACezmi A. Akdis
Cezmi A. Akdis
MAMubeccel Akdis
Mubeccel Akdis
TCThomas B Casale
Thomas B Casale
Marek JutelMarek Jutel
Marek Jutel
The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.